Eplontersen vs Inotersen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Transthyretin Amyloidosis with Polyneuropathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline
Eplontersen · Wainua
Marketed by AstraZeneca and partners
NCT04136184 · Phase 3 · completed
This open-label Phase 3 trial randomized 168 people with hereditary transthyretin amyloid polyneuropathy 6:1 to eplontersen or inotersen, but the primary efficacy comparisons were made between the eplontersen group and an external placebo group from an earlier, separate trial (NEURO-TTR). At Week 66 eplontersen was favored on neuropathy impairment (mNIS+7, LS mean difference -24.76, 95% CI -30.96 to -18.56) and on Norfolk quality of life (-19.74, 95% CI -25.63 to -13.84), and serum TTR fell by 70.42 percentage points more at Week 65, all with p<0.0001. Because the comparison group was neither randomized nor treated within this study, and no one was blinded, these results are more open to bias than a concurrent placebo-controlled comparison.
No aligned efficacy figure on record for this race.
Inotersen · Tegsedi
Rights held by Ionis Pharmaceuticals and partners
NCT01737398 · Phase 2/3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 172 patients. Both co-primary endpoints, a validated neuropathy impairment score and a quality-of-life questionnaire, showed statistically significant benefit with inotersen versus placebo at week 66.
No aligned efficacy figure on record for this race.
Results for Transthyretin Amyloidosis with Polyneuropathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Eplontersen: registry results are on file for Transthyretin Amyloidosis with Polyneuropathy, but their comparison mappings are not yet available.
Inotersen: registry results are on file for Transthyretin Amyloidosis with Polyneuropathy, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eplontersen's landscape · Inotersen's landscape